| Authors: |
Ehrenstein V; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark., Huang K; Pfizer Inc., New York, New York, USA., Kahlert J; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark., Bahmanyar S; Centre for Pharmacoepidemiology, Karolinska Institutet, Karolinska University Hospital SE, Stockholm, Sweden., Karlsson P; Centre for Pharmacoepidemiology, Karolinska Institutet, Karolinska University Hospital SE, Stockholm, Sweden., Löfling L; Centre for Pharmacoepidemiology, Karolinska Institutet, Karolinska University Hospital SE, Stockholm, Sweden., Nunes AP; Optum, Boston, Massachusetts, USA., Enger C; Optum, Boston, Massachusetts, USA., Bezemer ID; PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands., Kuiper JG; PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands., Hoti F; EPID Research, Espoo, Finland., Juuti R; EPID Research, Espoo, Finland., Korhonen P; EPID Research, Espoo, Finland., Mo J; Pfizer Inc., New York, New York, USA., Schachterle SE; Pfizer Inc., New York, New York, USA.; Department of Epidemiology and Biostatistics, School of Public Health and Health Policy, City University of New York, New York, New York, USA., Wilner KD; Pfizer Inc., New York, New York, USA., Rørth M; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark., Sørensen HT; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark. |
